ArticleBiotechnology journal2026
An Ad5-Based COVID-19 Vaccine Encoding SARS-CoV-2 Spike Glycoprotein Induces Measurable Antibody and Cytokine Responses in Mice.
Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Coated Bacterial Vaccine Platform Overcomes Weak Antigen Immunogenicity: A Functional Approach to GnRH-Based Immunocastration.Biotechnology journal · 2026Article
- SARS-CoV-2 Variants and Immune Evasion: Mapping the Future of Vaccine Design.Reviews in medical virology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The global SARS-CoV-2 pandemic has underlined the urgent need for effective vaccine platforms. Adenoviral vectors have gained attention due to their high transgene capacity, broad tissue tropism, and innate immunostimulatory properties. This study aimed to develop and evaluate a recombinant adenoviral vaccine, Ad5Spike, encoding the full-length SARS-CoV-2 Spike glycoprotein. The Ad5Spike vector was generated using Gateway Cloning Technology and produced by transient calcium phosphate-mediated transfection of 293A cells. Viral particles (VP) were purified via CsCl density gradient ultracentrifugation. Female BALB/c mice (6-8 weeks old, n = 5 per group per timepoint) were immunized intraperitoneally with 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.